Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An Ancestral 10-Bp Repeat Expansion in Vwa1 Causes Recessive Hereditary Motor Neuropathy Publisher Pubmed



Pagnamenta AT1 ; Kaiyrzhanov R2 ; Zou Y3 ; Daas SI4 ; Maroofian R2 ; Donkervoort S3 ; Dominik N2 ; Lauffer M5 ; Ferla MP1 ; Orioli A6, 7 ; Giess A6, 7 ; Tucci A6, 7 ; Beetz C8 ; Sedghi M9 Show All Authors
Authors
  1. Pagnamenta AT1
  2. Kaiyrzhanov R2
  3. Zou Y3
  4. Daas SI4
  5. Maroofian R2
  6. Donkervoort S3
  7. Dominik N2
  8. Lauffer M5
  9. Ferla MP1
  10. Orioli A6, 7
  11. Giess A6, 7
  12. Tucci A6, 7
  13. Beetz C8
  14. Sedghi M9
  15. Ansari B10
  16. Barresi R11, 12
  17. Basiri K10
  18. Cortese A2
  19. Elgar G6, 7
  20. Fernandezgarcia MA13
  21. Yip J2
  22. Foley AR3
  23. Gutowski N14
  24. Jungbluth H13, 15, 16
  25. Lassche S17
  26. Lavin T18
  27. Marcelis C19
  28. Marks P20
  29. Marinibettolo C11, 12
  30. Medne L21
  31. Moslemi AR22
  32. Sarkozy A23
  33. Reilly MM2
  34. Muntoni F23
  35. Millan F24
  36. Muraresku CC25
  37. Need AC6, 7
  38. Nemeth AH26, 27
  39. Neuhaus SB3
  40. Norwood F28
  41. Odonnell M20
  42. Odriscoll M20
  43. Rankin J29
  44. Yum SW30
  45. Zolkiplicunningham Z25, 31
  46. Brusius I5
  47. Wunderlich G32
  48. Karakaya M5
  49. Wirth B5
  50. Fakhro KA4, 33, 34
  51. Tajsharghi H35
  52. Bonnemann CG3
  53. Taylor JC1
  54. Houlden H2
Show Affiliations
Authors Affiliations
  1. 1. NIHR Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
  2. 2. Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, United Kingdom
  3. 3. Neuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health, Bethesda, MD, United States
  4. 4. Department of Human Genetics, Sidra Medicine, Doha, Qatar
  5. 5. Institute of Human Genetics, Center for Molecular Medicine Cologne (CMMC), Institute of Genetics, Center for Rare Diseases Cologne, University of Cologne, Cologne, Germany
  6. 6. William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
  7. 7. Genomics England, London, United Kingdom
  8. 8. Centogene AG, Rostock, Germany
  9. 9. Medical Genetics Laboratory, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  10. 10. Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  11. 11. The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom
  12. 12. Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
  13. 13. Department of Paediatric Neurology - Neuromuscular Service, Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
  14. 14. Department of Neurology, Royal Devon and Exeter NHS Trust, Exeter, United Kingdom
  15. 15. Randall Division of Cell and Molecular Biophysics Muscle Signalling Section, King's College London, London, United Kingdom
  16. 16. Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
  17. 17. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands
  18. 18. Department of Neurology, Salford Royal NHS Foundation Trust, Manchester, United Kingdom
  19. 19. Department of Genetics, Radboud University Medical Centre, Nijmegen, Netherlands
  20. 20. West Midlands Regional Clinical Genetics Service, Birmingham Health Partners, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom
  21. 21. Divisions of Neurology and Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, United States
  22. 22. Department of Pathology, University of Gothenburg, Sahlgrenska University Hospital, Sweden
  23. 23. The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, London, United Kingdom
  24. 24. GeneDx, Gaithersburg, 20877, MD, United States
  25. 25. Mitochondrial Medicine Frontier Program, Division of Human Genetics, Children's Hospital of Philadelphia, PA, United States
  26. 26. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
  27. 27. Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford, United Kingdom
  28. 28. Department of Neurology, King's College Hospital, London, United Kingdom
  29. 29. Peninsula Clinical Genetics Service, Royal Devon and Exeter NHS Trust, Exeter, United Kingdom
  30. 30. Division of Pediatric Neurology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
  31. 31. Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA, United States
  32. 32. Department of Neurology, Center for Rare Diseases Cologne, University Hospital Cologne, Cologne, Germany
  33. 33. College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
  34. 34. Department of Genetic Medicine, Weill Cornell Medical College, Doha, Qatar
  35. 35. School of Health Science, Division Biomedicine and Translational Medicine, University of Skovde, Sweden

Source: Brain Published:2021


Abstract

The extracellular matrix comprises a network of macromolecules such as collagens, proteoglycans and glycoproteins. VWA1 (von Willebrand factor A domain containing 1) encodes a component of the extracellular matrix that interacts with perlecan/collagen VI, appears to be involved in stabilizing extracellular matrix structures, and demonstrates high expression levels in tibial nerve. Vwa1-deficient mice manifest with abnormal peripheral nerve structure/function; however, VWA1 variants have not previously been associated with human disease. By interrogating the genome sequences of 74 180 individuals from the 100K Genomes Project in combination with international gene-matching efforts and targeted sequencing, we identified 17 individuals from 15 families with an autosomal-recessive, non-length dependent, hereditary motor neuropathy and rare biallelic variants in VWA1. A single disease-associated allele p.(G25Rfs∗74), a 10-bp repeat expansion, was observed in 14/15 families and was homozygous in 10/15. Given an allele frequency in European populations approaching 1/1000, the seven unrelated homozygote individuals ascertained from the 100K Genomes Project represents a substantial enrichment above expected. Haplotype analysis identified a shared 220 kb region suggesting that this founder mutation arose >7000 years ago. A wide age-range of patients (6-83 years) helped delineate the clinical phenotype over time. The commonest disease presentation in the cohort was an early-onset (mean 2.0 ± 1.4 years) non-length-dependent axonal hereditary motor neuropathy, confirmed on electrophysiology, which will have to be differentiated from other predominantly or pure motor neuropathies and neuronopathies. Because of slow disease progression, ambulation was largely preserved. Neurophysiology, muscle histopathology, and muscle MRI findings typically revealed clear neurogenic changes with single isolated cases displaying additional myopathic process. We speculate that a few findings of myopathic changes might be secondary to chronic denervation rather than indicating an additional myopathic disease process. Duplex reverse transcription polymerase chain reaction and immunoblotting using patient fibroblasts revealed that the founder allele results in partial nonsense mediated decay and an absence of detectable protein. CRISPR and morpholino vwa1 modelling in zebrafish demonstrated reductions in motor neuron axonal growth, synaptic formation in the skeletal muscles and locomotive behaviour. In summary, we estimate that biallelic variants in VWA1 may be responsible for up to 1% of unexplained hereditary motor neuropathy cases in Europeans. The detailed clinical characterization provided here will facilitate targeted testing on suitable patient cohorts. This novel disease gene may have previously evaded detection because of high GC content, consequential low coverage and computational difficulties associated with robustly detecting repeat-expansions. Reviewing previously unsolved exomes using lower QC filters may generate further diagnoses. © 2021 The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.